Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment
| Autor: | Fujiko Koyama, Hiroshi Hirosawa, Ai Sakuma, Miki Kobayashi, Satoshi Abe, Shiori Yamagata, Toru Ishikawa, Mitsuyuki Suzuki, Tomomi Nakano, Kazutaka Ohashi, Erina Hasegawa, Hiroko Abe, Aya Ueki, Yuka Maruyama, Hirohito Noguchi, Toshiaki Yoshida, Takako Fukazawa |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Cancer Research
medicine.medical_specialty Anemia Telaprevir 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Immunology and Microbiology (miscellaneous) Quality of life Pegylated interferon Internal medicine medicine In patient 030212 general & internal medicine business.industry Ribavirin Cancer Articles General Medicine medicine.disease Surgery chemistry Health survey 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Experimental and Therapeutic Medicine. 12:3353-3358 |
| ISSN: | 1792-1015 1792-0981 |
| Popis: | The rate of sustained virologic response (SVR) has increased in patients with chronic hepatitis C (CHC; genotype 1) since triple treatment with pegylated interferon (PEG-IFN), ribavirin (RBV) and telaprevir (TVR) was included in Japanese health insurance. However, side effects such as high-grade anemia and skin disorders means it is important to investigate the extent to which quality of life (QOL) is maintained during treatment. The impact on health-related (HR) QOL, as a result of TVR-based triple treatment was investigated long-term (48 weeks) in 34 patients (18 men, 16 women) following TVR-based triple treatment, using the 36-item short form health survey (SF-36). While scores for physical health were significantly lower during treatment, an improvement was seen in patients who showed complete response to treatment from 12 weeks following treatment (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|